http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112012020377-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6e299d7ac5545f806da3bc8d31536e2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 |
| filingDate | 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ea337eb306c22a483a5127a41f8e8a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f509678841cc952f6d6b648f57fd926 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1b7bb53f4e08d2614ba28cd5228c3e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9792111553e0b8c4843063d27845a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccc33fef75c2c2072264313c590db88e |
| publicationDate | 2019-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112012020377-B1 |
| titleOfInvention | USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME AND COMMERCIAL PACKAGING |
| abstract | use of one or more selected from the group consisting of a compound of formula (i), a racemic-diastereomeric mixture and an optical isomer of said compound, and a pharmaceutically acceptable salt and prodrug thereof, method, pharmaceutical composition and kit for treatment of cachexia and commercial packaging. The present invention relates to the use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the salt compound, for the manufacture of a medicament for treating cachexia. The invention also relates to a method for treating cachexia comprising administering the compound of the present invention or a pharmaceutical composition comprising it to a human or an animal. The invention further relates to the use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or salt, in combination with one or more second active agents. further, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof for treating said disease. |
| priorityDate | 2010-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 449.